AHA Scient

AHA Scientific Statement Redefines Neurodevelopmental Risks, Outcomes for Congenital Heart Disease

More than a decade of new knowledge about neurodevelopmental risk in people with congenital heart disease has changed the thinking about who is most at risk and the factors that impact neurological development, learning, emotions, and behaviours, according to a new American Heart Association scientific statement published in the journal Circulation “Neurodevelopmental difficulties are among the most common and enduring complications faced by people with congenital heart disease,” said Erica Sood, PhD, Nemours Children’s Health, Wilmington, Delaware. “These difficulties can affect a person’s ab...

Association between patent foramen ovale and migraine: evidence from a resting-state fMRI study

A relationship between migraine without aura (MO) and patent foramen ovale (PFO) has been observed, but the neural basis underlying this relationship remains elusive. Utilizing independent component analysis via functional magnetic resonance imaging,

Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adult...

BACKGROUND The unfavorable effect of proton pump inhibitors (PPIs) on cardiovascular (CV) outcomes and mortality was reported in the general population. We investigated the impact of PPIs on CV outcomes and total mortality in older people with dia...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Follicular
12:06

Follicular Lymphoma highlights of the ASH 2023 Congress

Presenter: Carla Casulo
Oncology : Hematology
ASH 2023
Highlights
9:22

Highlights of the ASH 2023 Congress

Presenter: Mikkael Sekeres
Oncology : Hematology
ASH 2023
Present an
14:07

Present and future of Multiple Myeloma management

Presenter: Xavier Leleu
Oncology : Hematology
ASH 2023
Ibrutinib-
5:010

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma

Presenter: Michael Wang
Oncology : Hematology
ASH 2023
Real-World
5:20

Real-World Outcomes With Brexucabtagene Autoleucel

Presenter: Swetha Kambhampati
Oncology : Hematology
ASH 2023
Frontline
8:20

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

Presenter: Adrian Wiestner
Oncology : Hematology
ASH 2023
Dramatical
6:21

Dramatically Worse Myeloma Outcomes in Real World vs. Trials

Presenter: Alissa Visram
Oncology : Hematology
ASH 2023
Multiple M
10:58

Multiple Myeloma highlights of ASH 2023 Congress

Presenter: Andrzej Jakubowiak
Oncology : Hematology
ASH 2023
Chronic My
12:36

Chronic Myeloid Leukemia highlights of ASH 2023 Congress

Presenter: Giuseppe Saglio
Oncology : Hematology
ASH 2023
Acute myel
4:57

Acute myeloid leukemia highlights of ASH 2023 Congress

Presenter: Eunice S. Wang
Oncology : Hematology
ASH 2023
Chronic My
5:50

Chronic Myeloid Leukemia: Novel Therapeutic Approaches

Presenter: Carmen Fava
Oncology : Hematology
ASH 2023
Non-Hodgki
8:31

Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress

Presenter: Umberto Vitolo
Oncology : Hematology
ASH 2023
Diagnostic
11:52

Diagnostic and Therapeutic Novelties of Multiple Myeloma Management

Presenter: Enrique Ocio
Oncology : Hematology
ASH 2023
Acute myel
4:45

Acute myeloid leukemia highlights of the ASH 2023 Congress

Presenter: Agnieszka Wierzbowska
Oncology : Hematology
ASH 2023
State of t
9:14

State of the art ALL treatement in 2023

Presenter: Marlise R. Luskin
Oncology : Hematology
ASH 2023
Revumenib
4:01

Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia

Presenter: Ibrahim Aldoss
Oncology : Hematology
ASH 2023
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology
Once-weekl
1:17

Once-weekly semaglutide in people with HFpEF and obesity

Presenter: Mikhail Kosiborod
Cardiology
Should ABP
1:31

Should ABPM parameters have a role in clinical practice?

Presenter: Paolo Palatini
Cardiology
On the mos
1:09

On the most important key points on the diagnosis of Hypertension in the new ESH2023 guidelines

Presenter: Bryan Williams
Cardiology
2023 ESC G
1:13

2023 ESC Guidelines for the Management of Endocarditis

Presenter: Michael A. Borger
Cardiology